Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Statement regarding Price Movement

1 May 2020 11:08

RNS Number : 6700L
Midatech Pharma PLC
01 May 2020
 

1 May 2020

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Statement regarding Price Movement

 

 

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines notes the recent movement in its share price and the Company confirms that it knows of no operational or corporate reason for the share price move.

 

As noted in the Company's recent announcements on 20 April 2020 and 31 March 2020 regarding the Company's strategic review, the Company continues in its Formal Sale Process and confirms that there are no material updates following those announcements.

 

The Company expects to announce its full year results for the year ended 31 December 2019 by the end of June 2020.

 

 

Midatech Pharma PLC

Stephen Stamp, CEO, CFO

Tel: +44 (0)1235 888300

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)

Joseph Green/ Laine Yonker

Tel: (646) 653-7030/ 7035

jgreen@edisongroup.com/ lyonker@edisongroup.com

 

 

Publication on website

A copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on the Company's website at www.midatechpharma.com in accordance with Rule 26.1 of the Code by no later than 12 noon (London time) on 21 April 2020. For the avoidance of doubt, the content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Takeover Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

Additional information

Panmure Gordon (UK) Limited ("Panmure"), is authorised and regulated by the Financial Conduct Authority in the United Kingdom. Panmure is acting as financial adviser in relation to the Takeover Code exclusively for Midatech and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters set out in this announcement and will not be responsible to anyone other than Midatech for providing the protections afforded to clients of Panmure or its affiliates, or for providing advice in relation to the contents of this announcement or any other matter referred to herein.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
SPMSSMFSFESSESI
Date   Source Headline
10th Mar 20169:00 amRNSNotice of Audited Full Year Results
29th Feb 20167:00 amRNSMidatech Celebrates Rare Disease Day
23rd Feb 20168:59 amRNSHolding(s) in Company
6th Jan 20167:00 amRNSPre-close Trading Update
4th Jan 20167:00 amRNSLicencing agreement signed with Emergex Vaccines
30th Dec 20157:00 amRNSClosing of product acquisition
23rd Dec 20157:00 amRNSIssue of Equity
18th Dec 20151:09 pmRNSDirector/PDMR Shareholding
18th Dec 20157:00 amRNSMidatech agrees to acquire Zuplenz®,
14th Dec 20157:00 amRNSAgreement with Centurion Pharma
9th Dec 20157:10 amRNSMidatech Appoints RBC as Joint Broker
7th Dec 20157:00 amRNSClosing of acquisition
3rd Dec 20152:34 pmRNSMerger Update: Amount of New Shares to be Issued
3rd Dec 20157:00 amRNSMerger Update: Acquisition of DARA BioSciences
19th Nov 20159:30 amRNSSupplemental Disclosure
25th Sep 20157:00 amRNSIssue of equity from exercise of share options
14th Sep 20157:00 amRNSHalf Yearly Report
2nd Sep 20159:10 amRNSMidatech to Present at Rodman & Renshaw Conference
2nd Sep 20157:00 amRNSNotice of Interim Results
13th Aug 20157:00 amRNSOcular Agreement with Ophthotech
12th Aug 20157:00 amRNSFiling of Form F-4 Registration Statement with SEC
23rd Jul 20157:00 amRNSInitiation of Phase IIa study of insulin delivery
26th Jun 201512:38 pmRNSDirector's Share Purchase
25th Jun 20153:03 pmRNSMidatech Pharma-Posting of Annual Financial Report
24th Jun 20157:00 amRNSDirector/PDMR Shareholding
23rd Jun 20153:43 pmRNSDirector/PDMR Shareholding
4th Jun 20157:00 amRNSProposed Acquisition of DARA BioSciences, Inc.
26th May 20152:05 pmRNSResult of AGM
26th May 20157:01 amRNSAnnual General Meeting
24th Apr 20154:12 pmRNSIssue of equity from exercise of share options
22nd Apr 20159:41 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th Apr 20157:04 amRNSPreliminary Results
14th Apr 20157:00 amRNSResearch Collaboration Signed
1st Apr 20157:00 amRNSMidatech Pharma - Board Change
31st Mar 20151:42 pmRNSChange of Registered Office Address
26th Mar 20157:00 amRNSNotice of Maiden Preliminary Results
23rd Mar 201510:43 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Mar 20157:00 amRNSResearch Collaboration Signed with Global Pharma
24th Feb 20157:00 amRNSTrading Update
19th Feb 20157:00 amRNSPositive Results in Proof-of-Concept Study
2nd Jan 20158:30 amRNSHolding(s) in Company
17th Dec 20147:00 amRNSAward of EU grant funding
9th Dec 20143:37 pmRNSHolding(s) in Company
8th Dec 201412:00 pmRNSMidatech Pharma acquires Q Chip

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.